Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | DHFR | P00374 | 1/20 | 0.51 |
| ▸ | PER2 | O15055 | 16/20 | 0.42 |
| ▸ | CRY2 | Q49AN0 | 9/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HBB | P68871 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17138491 | 1.00 | MAPT (0.65) | MAPTDHFRPER2CRY2TP53 | |
| SCHEMBL30145551 | 1.00 | MAPT (0.65) | MAPTDHFRPER2CRY2TP53 | |
| SCHEMBL15380361 | 1.00 | MAPT (0.65) | MAPTDHFRPER2CRY2TP53 | |
| SCHEMBL29558412 | 1.00 | MAPT (0.65) | MAPTDHFRPER2CRY2TP53 | |
| SCHEMBL29558790 | 1.00 | MAPT (0.65) | MAPTDHFRPER2CRY2TP53 | |
| SCHEMBL15380614 | 0.94 | MAPT (0.58) | MAPTDHFRPER2CRY2 | |
| SCHEMBL29623047 | 0.92 | DHFR (0.60) | MAPTDHFRPER2CRY2HBB | |
| SCHEMBL28406140 | 0.92 | DHFR (0.60) | MAPTDHFRPER2CRY2HBB | |
| SCHEMBL15380051 | 0.86 | MAPT (0.51) | MAPTDHFRPER2CRY2TP53 | |
| SCHEMBL22967261 | 0.84 | MAPT (0.48) | MAPTDHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190837-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | SYCHRONICITY PHARMA INC (US) | 2024-06-13 | — | — | US | disclosed |
| US-20220411399-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | SYCHRONICITY PHARMA INC (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220411399-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | SYCHRONICITY PHARMA INC (US) | 2022-12-29 | — | — | US | disclosed |
| EP-3939971-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| EP-3939971-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20210171495-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2021-06-10 | — | — | US | disclosed |
| US-20210171495-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2021-06-10 | — | — | US | disclosed |
| EP-3129366-B1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | SYNCHRONICITY PHARMA INC (US) | 2021-06-09 | — | — | EP | disclosed |
| EP-3129366-B1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | SYNCHRONICITY PHARMA INC (US) | 2021-06-09 | — | — | EP | disclosed |
| US-10759777-B2 | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | Synchronicity Pharma, Inc. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10759777-B2 | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | Synchronicity Pharma, Inc. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190241540-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2019-08-08 | — | — | US | disclosed |
| US-20190241540-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2019-08-08 | — | — | US | disclosed |
| US-20180334446-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2018-11-22 | — | — | US | disclosed |
| US-10005759-B2 | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | RESET THERAPEUTICS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005759-B2 | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | RESET THERAPEUTICS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| WO-2015157182-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | RESET THERAPEUTICS, INC. (US) | 2015-10-15 | — | — | WO | disclosed |
| US-20150284362-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2015-10-08 | — | — | US | disclosed |
| US-20150284362-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2015-10-08 | — | — | US | disclosed |
| US-20150284362-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241540-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | CRY1, CRY2, HCCS | MAPT 1593/4885DHFR 3329/4885PER2 188/4885 |
| US-20150284362-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | CRY1, CRY2, HCCS | MAPT 1593/4885DHFR 3329/4885PER2 188/4885 |
| US-20180334446-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | CRY1, CRY2, HCCS | MAPT 1593/4885DHFR 3329/4885PER2 188/4885 |
| US-20210171495-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | CRY1, CRY2, HCCS | MAPT 1593/4885DHFR 3329/4885PER2 188/4885 |
| US-10759777-B2 | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | CRY1, CRY2, HCCS | MAPT 1593/4885DHFR 3329/4885PER2 188/4885 |
| US-20220411399-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | CRY1, CRY2, HCCS | MAPT 1593/4885DHFR 3329/4885PER2 188/4885 |
| US-10005759-B2 | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | CRY1, CRY2, HCCS | MAPT 1593/4885DHFR 3329/4885PER2 188/4885 |
| US-20240190837-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | CRY1, CRY2, HCCS | MAPT 1593/4885DHFR 3329/4885PER2 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.